By nailing the primary endpoint in a phase 3 trial, Eli Lilly's Bruton tyrosine kinase (BTK) inhibitor Jaypirca has come one ...

Eli Lilly LLY announced that the phase III BRUIN CLL-313 study, evaluating its BTK inhibitor Jaypirca (pirtobrutinib) versus ...

E li Lilly is seeking a label expansion for earlier use of Jaypirca (pirtobrutinib) in treatment-naïve patients with chronic ...

Reversible BTK inhibitor Jaypirca (pirtobrutinib) has been shown in the BRUIN CLL-313 to significantly improve ...

Eli Lilly (LLY) recently announced positive results from its Phase 3 BRUIN CLL-313 trial, revealing significant ...

Jaypirca outperformed chemoimmunotherapy in progression-free survival for chronic lymphocytic leukemia patients in a Phase 3 ...

Eli Lilly has announced positive topline results from the Phase III BRUIN CLL-313 trial of Jaypirca (pirtobrutinib), sending ...

BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients INDIANAPOLIS, July 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...

Jaypirca (pirtobrutinib) is a brand-name prescription oral tablet that’s used in adults to treat certain types of blood cancers, including mantle cell lymphoma. Jaypirca is not available in a generic ...

Eli Lilly (LLY) saw notable developments in September, with the launch of Lilly TuneLab, an AI/ML platform designed to ...

The price you pay for Jaypirca (pirtobrutinib) may depend on factors such as your dosage and whether you have health insurance. Financial assistance may be available to help you with the cost of ...

Pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with a nominal P-value for superiority 0.05 BRUIN CLL-314 is the first-ever head-to-head Phase 3 study ...